Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.

Date publication

janvier 2011

Journal

Anticancer research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MERROUCHE Yacine

Tous les auteurs :
Freyer G, Duret A, Milano G, Chatelut E, Rebischung C, Delord JP, Merrouche Y, Lledo G, Etienne MC, Falandry C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/21273624

Résumé

Tolerability to irinotecan may be explained by pharmacogenomic polymorphisms. The purpose of this pharmacogenetic trial was to study the relevance of thymidylate synthase (TS) genotyping and of the isoform 1A1 of uridine diphosphate glucuronosyltransferase (UGT1A1) in order to tailor a combination chemotherapy regimen of 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in metastatic colorectal cancer.

Mots clés

Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Camptothecin, analogs & derivatives, Colorectal Neoplasms, drug therapy, DNA, Neoplasm, genetics, Female, Fluorouracil, therapeutic use, Follow-Up Studies, Genotype, Glucuronosyltransferase, genetics, Humans, Leucovorin, therapeutic use, Liver Neoplasms, drug therapy, Lung Neoplasms, drug therapy, Lymphatic Metastasis, Male, Middle Aged, Mutation, genetics, Neoplasm Staging, Pharmacogenetics, Pilot Projects, Polymerase Chain Reaction, Survival Rate, Thymidylate Synthase, genetics, Treatment Outcome, Young Adult

Référence

Anticancer Res.. 2011 Jan;31(1):359-66